Cited by 192Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentHormonal and reproductive studies

The DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index.

The role of androgens and the androgen receptor in prostate cancer.

Debes, Jose D, Tindall, Donald J·2002·Cancer Letters

DOI 10.1016/s0304-3835(02)00413-5

Open this paper in CoChat — free account

Abstract

Prostate cancer (PCa) is the leading diagnosed malignancy in men in western countries. The relationship between androgens and the androgen receptor (AR) has been studied extensively in PCa. Plasma levels of androgens show variations between different populations, and in many cases this correlates with PCa susceptibility. Indeed, exposure of the fetus to higher androgen concentrations appears to be a risk factor for PCa. The AR is present in the majority of PCa, and its activation by androgens leads to different proliferative, apoptotic and angiogenic events. These events are in turn mediated by dysregulation of cyclin-dependent kinases, apoptotic factors and even mutations in the AR. Although androgen ablation has been the mainstay non-surgical treatment for this disease, most tumors will eventually become refractory to treatment. Different cellular mechanisms appear to be involved in the androgen-independent progression of PCa, including cytokine and growth factor-mediated activation of the AR as well as neuroendocrine differentiation. Thus, an understanding of the cellular mechanisms involved in androgen action may lead to better therapeutic targets for PCa.

Integrity signals

Registry

Crossref · 10.1016/s0304-3835(02)00413-5

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer statistics, 2000
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Campbell's urology
Walsh, M. P. C. (1986) · Cited by 3,466
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E. L., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,992
STUDIES ON PROSTATIC CANCER
Huggins, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,694
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,243
The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
Chamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3181 · Cited by 1,149
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 594

Show all 77 references

Research works printed but not linked: 1

Debes, 2002, Proc. AACR, 43

Sorted by citations

Protective effect of green tea against prostate cancer: A case‐control study in southeast China
Jian, L., Xie, L., Lee, A. H., & Binns, C. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11550 · Cited by 369
Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities
Vashchenko, N. M., & Abrahamsson, P. (2004) · European Urology · doi:10.1016/j.eururo.2004.09.007 · Cited by 260
p300 in prostate cancer proliferation and progression.
Debes, J. D., Sebo, T. J., Lohse, C. M., Murphy, L. M., Haugen, D. A. L., & Tindall, D. J. (2003) · PubMed · Cited by 219
Self-citation
Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor
Wu, C., Altuwaijri, S., Ricke, W. A., Huang, S., Yeh, S., Zhang, C., Niu, Y., Tsai, M.-Y., & Chang, C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704940104 · Cited by 211
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.
Bakin, R. E., Gioeli, D. G., Sikes, R. A., Bissonette, E. A., & Weber, M. J. (2003) · PubMed · Cited by 201
High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in Prostate
Li, R., Wheeler, T. M., Dai, H., Frolov, A., Thompson, T. C., & Ayala, G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200407000-00013 · Cited by 185
Lycopene and Vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model
Siler, U., Barella, L., Spitzer, V., Schnorr, J., Lein, M., Góralczyk, R., & Wertz, K. (2004) · The FASEB Journal · doi:10.1096/fj.03-1116fje · Cited by 176
SENP1 Enhances Androgen Receptor-Dependent Transcription through Desumoylation of Histone Deacetylase 1
Cheng, J., Wang, D., Wang, Z., & Yeh, E. T. H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.6021-6028.2004 · Cited by 173
Analytical and compositional aspects of isoflavones in food and their biological effects
Mortensen, A., Kulling, S. E., Schwartz, H., Rowland, I. R., Ruefer, C. E., Rimbach, G. H., Cassidy, A., Magee, P. J., Millar, J., Hall, W. L., et al. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800478 · Cited by 169
Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.
Wright, M. E., Tsai, M.-J., & Aebersold, R. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0031 · Cited by 166
Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain
McEwan, I. J. (2004) · Endocrine-related cancer · doi:10.1677/erc.0.0110281 · Cited by 156
Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150
Self-citation
Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer
Ben-Batalla, I., Vargas-Delgado, M. E., von Amsberg, G., Janning, M., & Loges, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01184 · Cited by 149
“Due to the high affinity of SHBG for testosterone, this globulin is regulating the amount of unbound testosterone available for target tissues (10).”
Background
Ras signaling in prostate cancer progression
Weber, M. J., & Gioeli, D. G. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10683 · Cited by 153
Androgen receptor action in hormone‐dependent and recurrent prostate cancer
Agoulnik, I. U., & Weigel, N. L. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20811 · Cited by 141
Structure–function of human 3α-hydroxysteroid dehydrogenases: genes and proteins
Penning, T. M., Jin, Y., Steckelbroeck, S., Rižner, T. L., & Lewis, M. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.11.006 · Cited by 143
Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression
Shiota, M., Yokomizo, A., Tada, Y., Inokuchi, J., Kashiwagi, E., Masubuchi, D., Eto, M., Uchiumi, T., & Naito, S. (2009) · Oncogene · doi:10.1038/onc.2009.322 · Cited by 135
Human type 3 3α-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells
Rižner, T. L., Lin, H. K., Peehl, D. M., Steckelbroeck, S., Bauman, D. R., & Penning, T. M. (2003) · Endocrinology · doi:10.1210/en.2002-0032 · Cited by 132
Role of lycopene and tomato products in prostate health
Stacewicz‐Sapuntzakis, M., & Bowen, P. E. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.02.004 · Cited by 127
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases
Liepe, K., & Kotzerke, J. (2007) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32825a6adc · Cited by 120
Signal transduction in prostate cancer progression
Gioeli, D. G. (2005) · Clinical Science · doi:10.1042/cs20040329 · Cited by 117
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation
Ghosh, P., Malik, S. N., Bedolla, R. G., Wang, Y., Mikhailova, M., Prihoda, T. J., Troyer, D. A., & Kreisberg, J. I. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00835 · Cited by 110
Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage
Chatterjee, P., Schweizer, M. T., Lucas, J. M., Coleman, I., Nyquist, M. D., Frank, S. B., Tharakan, R., Mostaghel, E. A., Luo, J., Pritchard, C. C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127613 · Cited by 107
Interleukin-1β Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features
Liu, Q., Russell, M. R., Shahriari, K. S., Jernigan, D. L., Lioni, M., Garcia, F. U., & Fatatis, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3970 · Cited by 108
The hallmarks of castration-resistant prostate cancers
Katsogiannou, M., Ziouziou, H., Karaki, S., Andrieu, C., de Villeneuve, M. H., & Rocchi, P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.003 · Cited by 118
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases
Liepe, K., Kropp, J., Runge, R., & Kotzerke, J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601158 · Cited by 105
Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer
Takayama, K.-I., Suzuki, T., Fujimura, T., Takahashi, S., & Inoue, S. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0471 · Cited by 104
3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines
Xu, K., Ganapathy, K., Andl, T., Wang, Z., Copland, J. A., Chakrabarti, R., & Florczyk, S. J. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119311 · Cited by 104
Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus
Shiota, M., Yokomizo, A., Masubuchi, D., Tada, Y., Inokuchi, J., Eto, M., Uchiumi, T., Fujimoto, N., & Naito, S. (2009) · The Prostate · doi:10.1002/pros.21088 · Cited by 101
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
Debes, J. D., Comuzzi, B., Schmidt, L. J., Dehm, S. M., Culig, Z., & Tindall, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2837 · Cited by 92
Self-citation
Androgen receptor gene mutation, rearrangement, polymorphism.
Eisermann, K., Wang, D., Jing, Y., Pascal, L. E., & Wang, Z. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-4683.2013.09.15 · Cited by 94
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone
Ottewell, P. D., Wang, N., Meek, J., Fowles, C. A., Croucher, P. I., Eaton, C. L., & Holen, I. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0199 · Cited by 88
Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
Imamura, Y., & Sadar, M. D. (2016) · International Journal of Urology · doi:10.1111/iju.13137 · Cited by 88
Peroxisome Proliferator-Activated Receptor γ Coactivator-1α Interacts with the Androgen Receptor (AR) and Promotes Prostate Cancer Cell Growth by Activating the AR
Shiota, M., Yokomizo, A., Tada, Y., Inokuchi, J., Tatsugami, K., Kuroiwa, K., Uchiumi, T., Fujimoto, N., Seki, N., & Naito, S. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0302 · Cited by 83
Molecular alterations associated with LNCaP cell progression to androgen independence
Shi, X.-B., Ma, A., Tepper, C. G., Xia, L. P., Gregg, J. P., Gandour‐Edwards, R. F., Mack, P. C., Kung, H., & White, R. D. (2004) · The Prostate · doi:10.1002/pros.20039 · Cited by 83
Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer
Ashikari, D., Takayama, K., Tanaka, T., Suzuki, Y., Obinata, D., Fujimura, T., Urano, T., Takahashi, S., & Inoue, S. (2017) · Oncogene · doi:10.1038/onc.2017.225 · Cited by 80
Epigenetic regulation of nuclear steroid receptors
Leader, J. E., Wang, C., Fu, M., & Pestell, R. G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.05.024 · Cited by 81
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells
Baek, S. H., Ohgi, K. A., Nelson, C. A., Welsbie, D. S., Chen, C., Sawyers, C. L., Rose, D. W., & Rosenfeld, M. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510842103 · Cited by 81
Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer
Khurana, N., & Sikka, S. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092066 · Cited by 81
On the role of sex steroids in biological functions by classical and non-classical pathways. An update
Pillerová, M., Borbélyová, V., Hodosy, J., RILJAK, V., Renczés, E., Frick, K. M., & Tóthová, Ľ. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100926 · Cited by 79
Androgen and Its Receptor Promote Bax-Mediated Apoptosis
Lin, Y.-T., Kokontis, J. M., Tang, F., Godfrey, B., Liao, S., Lin, A., Chen, Y., & Xiang, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.5.1908-1916.2006 · Cited by 76
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain
Liepe, K., Runge, R., & Kotzerke, J. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0625-0 · Cited by 72
5α-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction
Rittmaster, R. S. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.016 · Cited by 71
Association of dopamine-β-hydroxylase and androgen receptor gene polymorphisms with Eysenck’s P and other personality traits
Turakulov, R. I., Jorm, A. F., Jacomb, P. A., Tan, X., & Easteal, S. (2003) · Personality and Individual Differences · doi:10.1016/j.paid.2003.08.011 · Cited by 67
Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression
Shiota, M., Takeuchi, A., Song, Y., Yokomizo, A., Kashiwagi, E., Uchiumi, T., Kuroiwa, K., Tatsugami, K., Fujimoto, N., Oda, Y., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0017 · Cited by 65
Protacs for Treatment of Cancer
Sakamoto, K. M. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e3181d35017 · Cited by 68
Inhibition of Androgen Receptor Transcriptional Activity as a Novel Mechanism of Action of Arsenic
Rosenblatt, A. E., & Burnstein, K. L. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0235 · Cited by 61
14-3-3ζ, a Novel Androgen-Responsive Gene, Is Upregulated in Prostate Cancer and Promotes Prostate Cancer Cell Proliferation and Survival
Murata, T., Takayama, K., Urano, T., Fujimura, T., Ashikari, D., Obinata, D., Horie‐Inoue, K., Takahashi, S., Ouchi, Y., Homma, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0281 · Cited by 59
Antioxidant Therapy Alleviates Oxidative Stress by Androgen Deprivation and Prevents Conversion From Androgen Dependent to Castration Resistant Prostate Cancer
Shiota, M., Song, Y., Takeuchi, A., Yokomizo, A., Kashiwagi, E., Kuroiwa, K., Tatsugami, K., Uchiumi, T., Oda, Y., & Naito, S. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.09.147 · Cited by 61
Antioxidants for prostate cancer chemoprevention: Challenges and opportunities
Thapa, D., & Ghosh, R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.027 · Cited by 58
Pregnane X Receptor as a Therapeutic Target to Inhibit Androgen Activity
Zhang, B., Cheng, Q., Ou, Z., Lee, J. H., Xu, M., Kochhar, U., Ren, S., Huang, M., Pflug, B. R., & Xie, W. (2010) · Endocrinology · doi:10.1210/en.2010-0708 · Cited by 57
Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer
Kominea, A., Konstantinopoulos, P. A., Kapranos, N., Vandoros, G. P., Gkermpesi, M., Andricopoulos, P., Artelaris, S., Savva, S., Varakis, I., Sotiropoulou‐Bonikou, G., et al. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0531-x · Cited by 57
27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer
Marwarha, G., Raza, S., Hammer, K. D. P., & Ghribi, O. (2017) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2017.05.012 · Cited by 59
Using DNA microarray analyses to elucidate the effects of genistein in androgen‐responsive prostate cancer cells: Identification of novel targets
Takahashi, Y., Lavigne, J. A., Hursting, S. D., Chandramouli, G. V. R., Perkins, S. N., Barrett, J. C., & Wang, T. T. Y. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20045 · Cited by 56
Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer
O’Reilly, D., JOHNSON, P. A., & Buchanan, P. (2019) · Steroids · doi:10.1016/j.steroids.2019.108497 · Cited by 57
Regucalcin is under‐expressed in human breast and prostate cancers: Effect of sex steroid hormones
Maia, C. J., Santos, C. R. A., Schmitt, F. C., & Socorro, S. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22158 · Cited by 54
Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition
Han, S., Brenner, J. C., Sabolch, A. N., Jackson, W., Speers, C. W., Wilder-Romans, K., Knudsen, K. E., Lawrence, T. S., Chinnaiyan, A. M., & Feng, F. Y.-C. (2013) · Neoplasia · doi:10.1593/neo.131604 · Cited by 54
Enhancement of androgen receptor expression induced by (R)‐methanandamide in prostate LNCaP cells
Sánchez‐Alonso, M. G., Sánchez, A. M., Ruiz-Llorente, L., & Díaz‐Laviada, I. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01349-8 · Cited by 54
Human Checkpoint Protein hRad9 Functions as a Negative Coregulator To Repress Androgen Receptor Transactivation in Prostate Cancer Cells
Wang, L., Hsu, C., Ni, J., Wang, P., Yeh, S., Keng, P., & Chang, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.5.2202-2213.2004 · Cited by 54
Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line
Wang, L. G., Ossowski, L., & Ferrari, A. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207654 · Cited by 51
Endocrine‐disrupting effects of methylparaben on the adult gerbil prostate
Costa, J. R., Campos, M. S., de Lima, R. F., Gomes, L. S., Marques, M. R., Taboga, S. R., Biancardi, M. F., Brito, P. V. A., & dos Santos, F. C. A. (2017) · Environmental Toxicology · doi:10.1002/tox.22403 · Cited by 49
Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
Pardo, J. C. T., de Porras, V. R., Gil, J., Pous, A. F., Puig‐Domingo, M., & Jordà, M. (2022) · Nutrients · doi:10.3390/nu14040851 · Cited by 55
The efficacy of natural bioactive compounds against prostate cancer: Molecular targets and synergistic activities
Mia, M. A. R., Dey, D., Sakib, M. R., Biswas, M. Y., Prottay, A. A. S., Paul, N., Rimti, F. H., Abdullah, Y., Biswas, P., Iftehimul, M., et al. (2023) · Phytotherapy Research · doi:10.1002/ptr.8017 · Cited by 49
Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells
Shiota, M., Yokomizo, A., Kashiwagi, E., Takeuchi, A., Fujimoto, N., Uchiumi, T., & Naito, S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.001 · Cited by 49
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions
Medová, M., Medo, M., Hovhannisyan, L., Muñoz-Maldonado, C., Aebersold, D. M., & Zimmer, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107617 · Cited by 48
Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets
Ramalingam, S., Ramamurthy, V. P., & Njar, V. C. O. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.07.006 · Cited by 51
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor
Kasina, S., & Macoska, J. A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.12.015 · Cited by 47
Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5
El-Haibi, C. P., Sharma, P., Singh, R., Gupta, P., Taub, D. D., Singh, S., & Lillard, J. W. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-64 · Cited by 46
Nuclear receptors and disease: androgen receptor
Gottlieb, B., Beitel, L. K., Wu, J., Elhaji, Y. A., & Trifiro, M. A. (2004) · Essays in Biochemistry · doi:10.1042/bse0400121 · Cited by 45
CLDN 8 , an androgen‐regulated gene, promotes prostate cancer cell proliferation and migration
Ashikari, D., Takayama, K., Obinata, D., Takahashi, S., & Inoue, S. (2017) · Cancer Science · doi:10.1111/cas.13269 · Cited by 44
Expression and function of gastrin‐releasing peptide ( GRP ) in normal and cancerous urological tissues
Ischia, J. J., Patel, O., Bolton, D. M., Shulkes, A., & Baldwin, G. S. (2014) · British Journal of Urology · doi:10.1111/bju.12594 · Cited by 42
Inhibition of Apoptosis in Prostate Cancer Cells by Androgens Is Mediated through Downregulation of c-Jun N-terminal Kinase Activation
Lorenzo, P. I., & Saatcioglu, F. (2008) · Neoplasia · doi:10.1593/neo.07985 · Cited by 41
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.
Sathya, G., Chang, C., Kazmin, D. A., Cook, C. E., & McDonnell, D. P. (2003) · PubMed · Cited by 41
Ubiquitin-specific peptidase 10, a deubiquitinating enzyme: Assessing its role in tumor prognosis and immune response
Ye, Z., Chen, J., Huang, P. C., Xuan, Z., & Zheng, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.990195 · Cited by 40
Systemic radionuclide therapy in pain palliation
Liepe, K., Runge, R., & Kotzerke, J. (2005) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/104990910502200613 · Cited by 39
Interaction between the Androgen Receptor and RNase L Mediates a Cross-talk between the Interferon and Androgen Signaling Pathways
Bettoun, D. J., Scafonas, A., Rutledge, S. J., Hodor, P. G., Chen, O., Gambone, C. J., Vogel, R., McElwee-Witmer, S., Bai, C., Freedman, L. P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500324200 · Cited by 39
Synthesis of a DNA-targeting nickel (II) complex with testosterone thiosemicarbazone which exhibits selective cytotoxicity towards human prostate cancer cells (LNCaP)
Heng, M. P., Sinniah, S. K., Teoh, W. Y., Sim, K. S., Ng, S. W., Cheah, Y. K., & Tan, K. W. (2015) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2015.05.095 · Cited by 38
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer
Izumi, K., Li, L., & Chang, C. (2014) · Clinical Investigation · doi:10.4155/cli.14.77 · Cited by 37
Sponging off nature for new drug leads
Andersen, R. J. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.04.012 · Cited by 40
Smart Drugs in Prostate Cancer
Vanderpoel, H. (2003) · European Urology · doi:10.1016/j.eururo.2003.08.011 · Cited by 37
Obesity and Cancer: Overview of Mechanisms
Nock, N. L., & Berger, N. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5515-9_5 · Cited by 35
Male Germ Cell–Associated Kinase, a Male-Specific Kinase Regulated by Androgen, Is a Coactivator of Androgen Receptor in Prostate Cancer Cells
Ma, A., Xia, L. P., Desai, S. J., Boucher, D. L., Guan, Y. F., Shih, H.-M., Shi, X.-B., White, R. D., Chen, H., Tepper, C. G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1636 · Cited by 34
Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer
McLeod, A., Stice, J. P., Wardell, S. E., Alley, H. M., Chang, C., & McDonnell, D. P. (2017) · The Prostate · doi:10.1002/pros.23467 · Cited by 33
A new prostate cancer therapeutic approach: Combination of androgen ablation with COX‐2 inhibitor
Cai, Y., Lee, Y., Li, G., Liu, S., Bao, B., Huang, J., Hsu, C., & Chang, C. (2008) · International Journal of Cancer · doi:10.1002/ijc.23481 · Cited by 33
Chemical Approaches to Controlling Intracellular Protein Degradation
Schneekloth, J. S., & Crews, C. M. (2004) · ChemBioChem · doi:10.1002/cbic.200400274 · Cited by 34
Tissue evidence of the testosterone role on the abnormal growth and aging effects reversion in the gerbil (Meriones unguiculatus) prostate
Scarano, W. R., Vilamaior, P. S. L., & Taboga, S. R. (2006) · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · doi:10.1002/ar.a.20391 · Cited by 33
Prognostic Significance of Neuroendocrine Differentiation in Patients With Gleason Score 8–10 Prostate Cancer Treated With Primary Radiotherapy
Krauss, D. J., Hayek, S., Amin, M., Ye, H., Kestin, L. L., Zadora, S., Vicini, F. A., Cotant, M. B., Brabbins, D. S., Ghilezan, M. I., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.064 · Cited by 32
Unveiling a pH-Responsive Dual-Androgen-Blocking Magnetic Molecularly Imprinted Polymer for Enhanced Synergistic Therapy of Prostate Cancer
Liu, X., Zhang, P., Song, H., Tang, X., Hao, Y., Guan, Y., Chong, T., Hussain, S., & Gao, R. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c13732 · Cited by 31
Biologically active marine natural products and their molecular targets discovered using a chemical genetics approach
Williams, D. E., & Andersen, R. J. (2019) · Natural Product Reports · doi:10.1039/c9np00054b · Cited by 32
Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: Roles of ERK/MAP kinase
Shigemura, K., Isotani, S., Wang, R., Fujisawa, M., Gotoh, A., Marshall, F. F., Zhau, H. E., & Chung, L. W. K. (2009) · The Prostate · doi:10.1002/pros.20944 · Cited by 32
The Androgen Receptor and Mechanisms for Androgen Independence in Prostate Cancer
Javidan, J., Deitch, A. D., Shi, X.-B., & White, R. D. (2005) · Cancer Investigation · doi:10.1080/07357900500202721 · Cited by 31
Human heterochromatin protein 1 isoform HP1β enhances androgen receptor activity and is implicated in prostate cancer growth
Shiota, M., Song, Y., Yokomizo, A., Tada, Y., Kuroiwa, K., Eto, M., Oda, Y., Inokuchi, J., Uchiumi, T., Fujimoto, N., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0321 · Cited by 31
Signaling Pathways That Control Apoptosis in Prostate Cancer
Ali, A. A., & Kulik, G. (2021) · Cancers · doi:10.3390/cancers13050937 · Cited by 34
Endocrine-disrupting chemicals as prostate carcinogens
Feijó, M., Carvalho, T. M. A., Fonseca, L. R. S., Vaz, C. V., Pereira, B. J., Cavaco, J. E. B., Maia, C. J., Duarte, A. P., Kiss‐Toth, E., Correia, S., et al. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01031-9 · Cited by 29
YB-1: The key to personalised prostate cancer management?
Bates, M., Boland, A. J., McDermott, N., & Marignol, L. H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.006 · Cited by 29
Crystal structure, docking study and structure–activity relationship of carborane-containing androgen receptor antagonist 3-(12-hydroxymethyl-1,12-dicarba-closo-dodecaboran-1-yl)benzonitrile
Ohta, K., Goto, T., Fujii, S., Kawahata, M., Oda, A., Ohta, S., Yamaguchi, K., Hirono, S., & Endo, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.04.017 · Cited by 29
Molecular signatures of soy-derived phytochemicals in androgen-responsive prostate cancer cells: A comparison study using DNA microarray
Takahashi, Y. K., Lavigne, J. A., Hursting, S. D., Chandramouli, G. V. R., Perkins, S. N., Kim, Y. S., & Wang, T. T. Y. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20247 · Cited by 29
The Discovery of Novel Human Androgen Receptor Antagonist Chemotypes Using a Combined Pharmacophore Screening Procedure
Voet, A. R. D., Helsen, C., Zhang, K. Y. J., & Claessens, F. (2013) · ChemMedChem · doi:10.1002/cmdc.201200549 · Cited by 27
Synthetic dimer of indole‐3‐carbinol: Second generation diet derived anti‐cancer agent in hormone sensitive prostate cancer
Garikapaty, V. P. S., Ashok, B. T., Tadi, K., Mittelman, A., & Tiwari, R. K. (2005) · The Prostate · doi:10.1002/pros.20350 · Cited by 27
PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors
Videira, A., Beckedorff, F., daSilva, L. F., & Verjovski‐Almeida, S. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-020-00691-x · Cited by 26

Authors: Debes, J. D., & Tindall, D. J.
Affiliations: Mayo Clinic (US)
Corresponding author: Tindall, Donald J
Venue: Cancer Letters
Publisher: Elsevier BV
Published: 2002-12
Volume: 187
Issue: 1-2
Pages: 1-7
ISSN: 0304-3835 (ISSN-L)
DOI: 10.1016/s0304-3835(02)00413-5
OpenAlex: W2141562227
Cited by: 191
References: 77
Citations by year: 2026: 3 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 4 · 2017: 10 · 2016: 5 · 2015: 7 · 2014: 7 · 2013: 8 · 2012: 10
FWCI: 3.08
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Cancer Letters (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 91956, P50CA091956)
National Institute of Diabetes and Digestive and Kidney Diseases (DK60920, R01DK060920)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords: prostate cancer, androgens, androgen receptor, androgen receptor mutations, androgen-independent progression, androgen deprivation therapy, neuroendocrine differentiation, cyclin-dependent kinases, apoptosis, angiogenesis, prenatal androgen exposure, therapeutic target
MeSH terms: Androgens, Humans, Male, Neoplasms, Hormone-Dependent, Prostate, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The role of androgens and the androgen receptor in prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks